Drug intelligence / Profile preview

SP-008

Development stage: Unknown
Lead developer: Sunny Pharmtech
Modality: Small Molecules
Administration: Oral

Overview

SP-008 is a small molecule oral capsule being developed by Sunny Pharmtech, a Contract Development and Manufacturing Organization (CDMO) based in Taiwan. The drug is intended for the treatment of melanoma and is currently in the bioequivalence (BE) study phase. This stage of development indicates that SP-008 is a generic version of an existing reference listed drug, designed to demonstrate identical pharmaceutical properties and biological availability. Sunny Pharmtech specializes in the development of high-potency APIs and complex formulations; SP-008 is classified as an anti-cancer agent with an Occupational Exposure Band (OEB) 2 rating, suggesting a relatively lower hazard profile compared to other oncology products in their pipeline, such as the OEB 5-rated SP-007.

Beyond the preview

Go deeper on SP-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP-008.

Explore the full profile